{% load static %}
<!DOCTYPE html>
<html>
    <head>
        <title>Vertex Pharmaceuticals Incorporated Stock - FluxCache</title>
        <meta charset="UTF-8"/>
        <link rel="stylesheet" type="text/css" href="{% static 'css/template.css' %}"/>
    </head>
    <body>
        <div class="backgroundImg" style = 'background-image: url("/static/image/individual_header.jpg")'>
            <h1 style="font-size: 100px; text-align:center; font-family:sans-serif; color:white">FluxCache-Vertex Pharmaceuticals Incorporated Stock</h1>
        </div>
        <div class="navbarDiv">
            <a id="tab1" href="/Home">Home</a>
            <a id="tab2" class="active" href="/MarketTrends.html">Market Trends</a>
            <a id="tab3" href="/about_us.html">About Us</a>
            <a id="tab4" href="/contact.html">Contacts</a>
        </div>
        <div class="clearfix">
            <div class="column logo">
                <img src="{% static 'image/tesla_logo.png' %}" height="100px;"/>
            </div>
            <div class="column content">
                <h2 style="color:rgb(43, 56, 48);"><strong>Vertex Pharmaceuticals Incorporated <br> (VRTX-NASDAQ)</strong></h2>
                <p style="color: rgb(19, 18, 18)">This stock is valued at 228.08. 
                    Today, the stock had an opening of 228.13.<br>Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.</p>
            </div>
        </div>
        <div class="graph_intro">
            <h3>VRTX Through the Past Month</h3>
        </div>
        <div class="graph_border">
            <img src="{% static 'mysite\static\image\topStock2.jpg' %}" height="520px;"/>
        </div>
    </body>
</html>